About the Journal
Focus and Scope
Progress in Drug Discovery & Biomedical Science (PDDBS) is an open access journal dedicated to the exchange of information and understandings about the research in areas of drug discovery and biomedical science based on the principles established through international conventions.
PDDBS covering both the fundamental and application aspects of drug discovery & biomedical science and welcoming papers having a good interdisciplinary approach.
Coverage includes:
-Plant, microbes bioactives
-Basic or applied biomedical research
-Toxicology & pharmacology
- Molecular/cell biology
- Drug delivery
- Therapeutic strategies/targets
- ADME
- Clinical trials
- Structural Biology and Biomolecular Modelling
- Curriculum, instruction and pedagogy
Publication Frequency
The publication frequency of Progress in Drug Discovery and Biomedical Science is annually (December).
Editorial and Peer Review Process
After submission, editors assess the suitability of manuscripts, selecting those that align with the journal's scope and appeal to readers. Manuscripts that do not conform to the general criteria for publication will be returned to authors without detailed review. The chosen manuscripts are then sent to two or more reviewers for evaluation. Progress In Microbes and Molecular Biology adopts a double-blind peer review process. The editors strive to reach decisions on these papers within three weeks from the submission date. Reviewers have the authority to recommend publication, revisions, or rejection. They assess the manuscript's originality, technical quality, clarity, and relevance to the field. The editors consider the reviewers' opinions in relation to the journal's scope and objectives, ultimately making the final decision on each manuscript. If major revisions are necessary for publication, authors are generally given four weeks to complete them, while a shorter timeframe is given when minor revision is needed. Accepted papers will be published online as soon as possible. However, any major changes made after acceptance will undergo review and may result in publication delays.
The editors and Editorial Board members are not involved in decisions regarding papers they have authored, papers written by their family members or colleagues, or papers related to products or services in which the editor has a personal interest. Such submissions follow the journal's standard procedures, with peer review conducted independently of the relevant editor and their research groups.
When a manuscript is submitted for review, the journal's editorial team removes any identifying information that could reveal the authors' identities. This includes redacting the authors' names, affiliations, and other details that could potentially disclose authors’ identities. Similarly, the reviewers' identities are also concealed from the authors.
During the review process, the manuscript is assigned to (2 to 3) independent reviewers who assess its quality, methodology, significance, and contribution to the field. The reviewers provide feedback, suggestions, and criticisms without knowing the authors' identities. Likewise, the authors are unaware of the identities of the reviewers assessing their manuscript. This double-blind review process creates a fair and unbiased evaluation system, where manuscripts are assessed solely on scientific content. By maintaining confidentiality, this process aims to minimize potential biases arising from factors unrelated to the research.
Once the review process is complete, the editor-in-chief or the editorial team considers the reviewers' feedback and decides on whether to accept the manuscript for publication, request revisions, or reject it. The authors receive the reviewers' comments and recommendations for improving their work, but remain unaware of the reviewers' identities.
Journal Publication Ethics
Progress in Drug Discovery and Biomedical Science's manuscript management adheres to “Code of Conduct for Journal Editors and Code of Conduct for Publishers” and Best Practise as stipulated by the Committee on Publication Ethics (COPE) to prevent misconduct of research papers. The editorial committee consider the ethical publishing practices as fundamental part of ethical responsibilities among authors. The editors are committed to maintaining high standards through a rigorous double-blinded peer review along with strict ethical policies. In order to avoid the plagiarism, the author shall provide all the information about the novelty and importance of the findings including the similarity index report by iThenticate/Turnitin of 30% or less. In addition, the editor of the journal is doing our best to ensure fair, unbiased, and transparent peer review and editorial decisions. When an author discovers a significant error or inaccuracy in his/her own published work, it is the author's obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper. If the editor or the publisher learns from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper. Any detected cases of misconduct, whether on the part of authors, reviewers or editors, will be vigorously pursued. And finally, each article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Author(s) shall retain the copyright of their work and grant the Journal/Publisher right for the first publication with the work simultaneously licensed under: i. Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license allows for the copying, distribution and transmission of the work, provided the correct attribution of the original creator is stated. Adaptation and remixing are also permitted; ii. This broad license intends to facilitate free access to, as well as the unrestricted reuse of, original works of all types for non-commercial purposes; iii. The author(s) permits HH Publisher to publish this article that has not been submitted elsewhere.
Open Access Policy
Progress in Drug Discovery and Biomedical Science is a Gold Open access journal. Author(s) shall retain the copyright of their work, but grant to the Publisher a license to publish.
Progress in Drug Discovery and Biomedical Science works under the license of Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) that allows copying, distribution, and transmission of the published work with the acknowledgement of original creator. This broad license intends to facilitate free access to, as well as the unrestricted reuse of, original works of all types.
Charges
Article Processing Charge
If the manuscript is accepted for publication, the author is required to pay for an Article Publication Charge (APC) to cover publication costs.
APC is USD40 or RM150.
Revenue Sources
Progress in Drug Discovery and Biomedical Science is financially supported by Open-Access model system under the HH Publisher. Business models or revenue sources (e.g., author fees, subscriptions, advertising, reprints, institutional support, and organizational support) shall be clearly stated or otherwise evident on the journal’s website. Publishing fees or waiver status should not influence editorial decision making.
Advertising
Progress in Drug Discovery and Biomedical Science shall state the advertising policy if relevant, including what types of adverts will be considered, who makes decisions regarding accepting adverts and whether they are linked to content or reader behaviour (online only) or are displayed at random. Advertisements should not be related in any way to editorial decision making and shall be kept separate from the published content.
Direct marketing
Any direct marketing activities, including solicitation of manuscripts that are conducted on behalf of the Progress in Drug Discovery and Biomedical Science, shall be appropriate, well targeted, and unobtrusive. Information provided about the publisher or journal is expected to be truthful and not misleading for readers or authors.